Neoproteomics Ab
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Neoproteomics Ab - overview
Established
2000
Location
Stockholm, -, Sweden
Primary Industry
Healthcare
About
Neoproteomics Ab is a Swedish company focused on developing advanced proteomics solutions that enhance analytical capabilities for life sciences, addressing complexities in protein analysis and facilitating research in drug discovery and personalized medicine. Founded in 2000 in Stockholm, Sweden, Neoproteomics Ab provides innovative proteomics solutions aimed at advancing life sciences research. The company has undergone no significant pivots and does not have known subsidiaries. In 2014, Acacia Asset invested an undisclosed amount in the company, highlighting its potential as an investment target.
The founder's individual history and any prior ventures are not available. Neoproteomics specializes in advanced proteomics solutions, offering high-throughput platforms designed for in-depth analysis of protein structures and functions. Their products cater to various applications including drug discovery, biomarker identification, and personalized medicine, serving clients in North America, Europe, and Asia-Pacific. Their solutions address challenges in protein interactions and quantification, enhancing research workflows and experimental outcomes for academic and biotech institutions.
In 2023, Neoproteomics reported a revenue of USD 0. 00, with an EBITDA of USD -14,428. 50. The company's revenue model focuses on direct sales of proprietary proteomics platforms, often through subscription or licensing agreements tailored for institutional clients, alongside B2B transactions providing custom proteomic analysis and collaborative research.
Neoproteomics is focused on expanding its product offerings and entering new markets. While specifics on upcoming products and release dates are not detailed, the company aims to broaden its reach in the healthcare and research sectors. Recent funding from Acacia Asset in 2014 will be utilized to support these initiatives and enhance their capabilities in proteomics, aligning with their strategic vision for growth in diverse geographic regions.
Current Investors
ACACIA Asset Management
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories
Website
http://neoproteomics.com/
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Neoproteomics Ab - timeline of key events
Neoproteomics Ab - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | 102,000 | 374,000 | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | 266.7% | (100.0%) | - | - | - | - | - | - | - |
| EBITDA (USD) | (724,017) | (1,119,390) | (1,933,245) | (3,088,368) | (2,616,938) | (3,863,428) | (1,506,595) | (901,533) | (765,891) | (212,000) | (19,000) | - | - | - |
| Operating Income (USD) | (724,017) | (1,119,390) | (1,943,467) | (3,107,739) | (2,636,311) | (3,882,802) | (1,526,583) | (910,044) | (765,891) | (212,000) | (19,000) | - | - | - |
| Operating Margin | - | - | - | - | (2584.6%) | (1038.2%) | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | (2565.6%) | (1033.0%) | - | - | - | - | - | - | - | - |
| NET Income (USD) | (724,017) | (1,119,415) | (130,565) | 91,911 | 12,691 | 7,140 | (1,531,573) | (923,268) | (797,528) | (258,000) | (66,000) | - | - | - |
| % Net Margin | - | - | - | - | 12.4% | 1.9% | - | - | - | - | - | - | - | - |
Neoproteomics Ab - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | Neoproteomics Ab | - |
Displaying 1 - 1 of 1
Neoproteomics Ab - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.